Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review
Rheumatology International · 2024
DOI: 10.1007/s00296-024-05718-x ↗Kurz gefasst
Fallbericht in der Zeitschrift Rheumatology International, 2024. Verfasst von Rada Miskovic und 7 weiteren Autor:innen. Beteiligte Einrichtung: Clinic of Allergy and Immunology, University Clinical Centre of Serbia, Koste Todorovica 2, 11000, Belgrade, Serbia. rada_delic@hotmail.com. Hauptthemen laut MEDLINE: Vasculitis, Leukocytoclastic, Cutaneous, COVID-19 Vaccines, COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
With the global introduction and widespread administration of COVID-19 vaccines, there have been emerging reports of associated vasculitis, including leukocytoclastic cutaneous vasculitis (LCV). In this paper, we present a case of a 68-year-old female patient who developed painful purpuric skin lesions on her feet 12 days after administration of the inactivated COVID-19 vaccine BBIBP Cor-V with histopathological confirmation of LCV and no signs of systemic involvement. The case is followed by a comprehensive literature review of documented LCV cases associated with COVID-19 vaccination with overall 39 articles and 48 cases of LCV found in total. In the majority of cases (56.3%) the first symptom occurred after the first dose of the COVID-19 vaccine, with symptoms manifesting within an average of seven days (6.8 ± 4.8) post-vaccination. The adenoviral vaccine Oxford-AstraZeneca (41.7%) and the mRNA vaccine Pfizer-BioNTech (27.1%) were most frequently associated with LCV occurrences. On average, LCV resolved within 2.5 (± 1.5) weeks. The preferred treatment modality were glucocorticoids, used in 70.8% of cases, resulting in a positive outcome in most cases, including our patient. While the safety of a subsequent dose appears favorable based on our review, individual risk-benefit assessment is crucial. This review emphasis the importance of considering COVID-19 vaccination as a potential trigger for the development of cutaneous vasculitis. Despite rare adverse events, the benefits of the COVID-19 vaccination outweigh the risks, highlighting the importance of immunization programs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinic of Allergy and Immunology, University Clinical Centre of Serbia, Koste Todorovica 2, 11000, Belgrade, Serbia. rada_delic@hotmail.com.
- Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000, Belgrade, Serbia. rada_delic@hotmail.com.
- Clinic of Allergy and Immunology, University Clinical Centre of Serbia, Koste Todorovica 2, 11000, Belgrade, Serbia.
- Faculty of Medicine, University of Belgrade, Dr Subotica 8, 11000, Belgrade, Serbia.
- Clinic of Dermatovenereology, University Clinical Centre of Serbia, Koste Todorovica 2, 11000, Belgrade, Serbia.
- Clinic of Nephrology, University Clinical Centre of Serbia, Koste Todorovica 2, 11000, Belgrade, Serbia.
ORCID-Profile: Rada Miskovic, Sara Radovic, Snezana Arandjelovic, Aleksandra Plavsic, Vesna Reljic, Jelena Peric, Voin Brkovic, Maja Stojanovic
Zitieren
APA
Miskovic, R., Radovic, S., Arandjelovic, S., Plavsic, A., Reljic, V., Peric, J., Brkovic, V., & Stojanovic, M. (2024). Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review. Rheumatology International. https://doi.org/10.1007/s00296-024-05718-x
Vancouver
Miskovic R, Radovic S, Arandjelovic S, Plavsic A, Reljic V, Peric J, et al. Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review. Rheumatology International. 2024. doi:10.1007/s00296-024-05718-x
BibTeX
@article{Miskovic2024,
author = {Miskovic, Rada and Radovic, Sara and Arandjelovic, Snezana and Plavsic, Aleksandra and Reljic, Vesna and Peric, Jelena and Brkovic, Voin and Stojanovic, Maja},
title = {Onset of leukocytoclastic vasculitis following covid-19 vaccination: case based comprehensive review},
journal = {Rheumatology International},
year = {2024},
doi = {10.1007/s00296-024-05718-x}
}
EUVIMED